- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03207100
Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment (ASSICHH)
December 5, 2023 updated by: Hong Yang
Clinical Study of the Safety and Efficacy of Analgesia-first Minimal Sedation as an Early Antihypertensive Treatment for Spontaneous Intracerebral Hemorrhage
This study evaluates safety and efficacy of analgesia-first minimal sedation as an early antihypertensive treatment for spontaneous intracerebral hemorrhage.
The analgesia-first minimal sedation strategy relies on the remifentanil-mediated alleviation of pain-induced stress response and the antisympathetic activity of dexmedetomidine to restore the elevated blood pressure to normal level in patients with spontaneous intracerebral hemorrhage.
This strategy allows rapid stabilization of blood pressure, and its use as a pre-treatment for patients on mechanical ventilation prior to painful procedures reduces blood pressure variability and thereby results in etiologic treatment.
It is more effective in blood pressure control than conventional symptomatic antihypertensive treatment, reduces the incidence of early hematoma expansion and improves prognosis, ,lowers healthcare workers workload, increases patient adherence, and improves healthcare worker satisfaction.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Spontaneous intracerebral hemorrhage (ICH) is hemorrhage in the brain parenchyma caused by non-traumatic spontaneous rupture of cerebral artery, arteriole, vein and capillary in adults.
ICH is a common problem, with subarachnoid hemorrhage.
About 90% ICH patients have increased blood pressure (BP) that usually occurs immediately after disease onset.
BP elevation in the acute phase of ICH is associated with poor prognosis, and its mechanism of action includes the local increase of initial hemorrhage, early hematoma expansion at hemorrhagic sites, the increased risk of early recurrent hemorrhage, serious cerebral edema, and recurrent stroke, this affects the most within the few hours following the onset of the disease.
The current American Heart Association guidelines recommended early antihypertensive treatment and suggested that rapid decrease of BP to 140 mmHg is safe in ICH patients with no obvious antihypertensive contraindications.
However, the significant differences between large studies conducted in recent years have led to great controversy on the effect of early antihypertensive treatment in acute ICH and disease prognosis.
A meta-analysis of early antihypertensive treatment for ICH showed that differences in early BP control rate and BP increase variability are also the major causes of inconsistency between these studies.
There is currently no consensus on the best antihypertensive regimen as it is difficult to reach the optimal BP level timely.
Some studies have shown that stress response, pain, ICP increase and pre-onset BP elevation are factors that cause acute BP increase in ICH patients.
In particular, restlessness, sleep deprivation, and stress due to intolerable pain can lead to dramatic BP and intracranial pressure (ICP) increases, further lead to secondary intracerebral hematoma expansion and subsequently cause neurologic degeneration and cerebral tissue damage.
Therefore, the primary principles of ICH acute BP increase treatment are to keep quiet, restore BP to normal level, stably reduce BP, decrease BP variability, lower the chance of recurrent hemorrhage, and thereby improve long-term prognosis.
Traditional antihypertensive treatment can only resolve the issue of BP elevation but not the root cause of disease.
Analgesia and sedation is a critical component of and a global consensus in the clinical management of ICH patients.
Remifentanil is a fentanyl μ-type opioid receptor agonist with strong and fast-acting analgesic effects, does not induce ICP elevation and can alleviate pain induced by sputum aspiration, body turning and back clapping in severe patients.
A randomized trial on patients with craniocerebral injury has indicated that a remifentanil-based sedation strategy can significantly reduce the amount of sedative used and shorten the time of mechanical ventilation without affecting the functional assessment of the nervous system.
Dexmedetomidine is an α2-adrenergic agonist that inhibits sympathetic activity by activating the pre-synaptic α2-receptor in the locus coeruleus, which in turn reduces norepinephrine release, that only slightly affects consciousness and breathing and helps patients with craniocerebral injury stay conscious while under sedation, allowing real-time functional assessment of the nervous system.
Therefore, the research group developed a treatment strategy in which sufficient analgesia is applied in combination with a minimal sedation program as an effective and safe early an- tihypertensive treatment.We hypothesize that applying sufficient analgesia in combination with a minimal sedation program will involve the use of remifentanil for pain relief and dexmedetomidine for antisympathetic activity to restore elevated BP to normal levels in patients with spontaneous ICH, and we further hypothesize that this strategy will be more effective than conventional symptomatic antihypertensive treatment for controlling BP.
Study Type
Interventional
Enrollment (Actual)
338
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Xuanwu Hospital Capital Medical University
-
-
Chongqing
-
Chongqing, Chongqing, China, 400037
- Xinqiao Hospital of Army Medical University
-
-
Gansu
-
Lanzhou, Gansu, China, 730000
- The First Hospital of Lanzhou University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Guangdong 999 Brain Hospital
-
Guangzhou, Guangdong, China, 510630
- The Third Affiliated Hospital of Southern Medical University
-
Guangzhou, Guangdong, China, 510900
- The Fifth Affiliated Hospital of Southern Medical University
-
Maoming, Guangdong, China, 525000
- Maoming People's Hospital
-
Shenzhen, Guangdong, China, 518035
- The second people's Hospital of Shenzhen
-
Zhongshan, Guangdong, China, 528400
- Zhongshan People's Hospital
-
Zhuhai, Guangdong, China, 519000
- The Fifth Affiliated Hospital Sun-yet sen University
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- The people's hospital of Guangxi Zhuang Autonomous Region
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Henan Provincial People's Hospital
-
-
Hunan
-
Hengyang, Hunan, China, 421001
- The Second Hospital University of South China
-
Huaihua, Hunan, China, 418000
- The First Affiliated Hospital of HuNan University of Medicine
-
-
Shandong
-
Qingdao, Shandong, China, 266035
- Qilu Hospital of Shandong University
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830054
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- The First Affiliated Hospital of Kuming Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Definitive diagnosis of ICH-induced acute brain injury by CT;
- Systolic BP ≥150 mmHg for at least twice;
- >18 years old;
- Feasible for emergency antihypertensive treatment and real-time BP monitoring;
- Disease onset is within 24h;
- ICU or stroke unit admission within 24h.
Exclusion Criteria:
- Subject has contraindications for emergency intensified antihypertensive treatment;
- Intracranial hemorrhage secondary to intracranial tumor, recent trauma, cerebral infarction and thrombolytic therapy;
- History of ischemic stroke within 30 days before disease onset;
- Clinical or imaging examination reveals an expected high mortality in subject within the next 24h;
- Presence of dementia or significant post-stroke disability;
- Coagulation disorder caused by drugs or hematologic diseases;
- Allergy to opioids;
- Interference test result, assessment and follow-up of comorbidity;
- Presence of sinus arrest, borderline rhythm, grade II and above atrioventricular block and malignant arrhythmia;
- Individual is pregnant or lactating;
- Currently participating in other drug studies or clinical trials;
- Subject or guardian is unwilling to provide his/her informed consent form, or subject is highly unable to persist with the study and follow-up;
- Subject's participation in the study will increase his/her study-related risk, and other reasons that make the subject unsuitable for the study as determined by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Analgesia-first minimal sedation group
Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
|
Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients.
BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h.
BP will be measured again after 15 min of continuous infusion of dexmedetomidine.
If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range.
Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
|
Active Comparator: Antihypertensive drug treatment group
Using routine antihypertensive drugs to implement antihypertensive therapy.
|
Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center.
Urapidil, nicardipine, and labetalol will be used in this group.
Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min.
Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min.
Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic BP control rate at 1h post-treatment initiation
Time Frame: 1h post-treatment initiation
|
The number of patients who systolic BP decreased to <140 mmHg at 1h post-treatment initiation compared to the total number of each group.
|
1h post-treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematoma growth at 24 h
Time Frame: 24h of treatment
|
Head CT re-examination is required for the subjects after 24h of treatment.Hematoma expansion is defined as V2-V1≥12.5 cm³ or (V2-V1)/V1>33% (V1 and V2 represent the hematoma volume in the two CT scans, respectively).
|
24h of treatment
|
BP variability
Time Frame: Up to 7 days
|
BPs are also recorded every hour from hour 2 to 24 post-treatment, and monitored on d2-d7 of treatment of recorded every 6h daily (4 times per day); BP Coefficient of Variation (CV) = (standard deviation of BP/mean of systolic BP).
|
Up to 7 days
|
Neurologic function
Time Frame: Up to 7 days
|
Assessed once every morning using the National Institutes of Health Stroke Scale (NIHSS), Glasgow Coma Scale scores (GCS), Richmond Agitation-Sedation Scale (RASS), Nonverbal Adult Pain Assessment Scale (NVPS), Reaction Level Scale (RLS).
|
Up to 7 days
|
Duration of ICU treatment and mechanical ventilation
Time Frame: Up to 7 days
|
Duration of ICU treatment and mechanical ventilation
|
Up to 7 days
|
Healthcare worker satisfaction
Time Frame: 7 day or discharge from ICU (if patients discharge from ICU in 7 days)
|
Questionnaire is designed based on the Copenhagen Psychosocial Questionnaire, with a parameter for self-assessed workload.
|
7 day or discharge from ICU (if patients discharge from ICU in 7 days)
|
cerebral tissue oxygenation index (TOI)
Time Frame: Up to 7 days and around sputum aspiration
|
Assess changes in the TOI after sputum aspiration in mechanical ventilation patients
|
Up to 7 days and around sputum aspiration
|
28-day mortality and disability rate
Time Frame: 28 days
|
Using a binary indicator of the patient's death or dependency at 28 days, with dependency being defined by a score of 3 to 5 on the modified Rankin Score (mRS)
|
28 days
|
90-day mortality and disability rate
Time Frame: 90 days
|
Using a binary indicator of the patient's death or dependency at 90 days, with dependency being defined by a score of 3 to 5 on the modified Rankin Score (mRS)
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Wen-Jin Chen, Xuanwu Hospital, Beijing
- Study Chair: Hong Yang, Dr, The Third Affiliated Hospital of Southern Medical University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, Coursin DB, Herr DL, Tung A, Robinson BR, Fontaine DK, Ramsay MA, Riker RR, Sessler CN, Pun B, Skrobik Y, Jaeschke R; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the Intensive Care Unit: executive summary. Am J Health Syst Pharm. 2013 Jan 1;70(1):53-8. doi: 10.1093/ajhp/70.1.53.
- van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604-7. doi: 10.1161/01.str.19.5.604.
- Rodriguez-Luna D, Pineiro S, Rubiera M, Ribo M, Coscojuela P, Pagola J, Flores A, Muchada M, Ibarra B, Meler P, Sanjuan E, Hernandez-Guillamon M, Alvarez-Sabin J, Montaner J, Molina CA. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013 Sep;20(9):1277-83. doi: 10.1111/ene.12180. Epub 2013 May 5.
- Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013 Jun 20;368(25):2355-65. doi: 10.1056/NEJMoa1214609. Epub 2013 May 29.
- Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006 Jul;5(7):603-12. doi: 10.1016/S1474-4422(06)70495-1.
- Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol. 2014 Aug;13(8):844-54. doi: 10.1016/S1474-4422(14)70120-6. Erratum In: Lancet Neurol. 2014 Sep;13(9):863.
- Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008 May;7(5):391-9. doi: 10.1016/S1474-4422(08)70069-3. Epub 2008 Apr 7.
- Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001 May 10;344(19):1450-60. doi: 10.1056/NEJM200105103441907. No abstract available.
- Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993 Jul;24(7):987-93. doi: 10.1161/01.str.24.7.987.
- Chen ST, Chen SD, Hsu CY, Hogan EL. Progression of hypertensive intracerebral hemorrhage. Neurology. 1989 Nov;39(11):1509-14. doi: 10.1212/wnl.39.11.1509.
- Broderick JP, Brott TG, Tomsick T, Barsan W, Spilker J. Ultra-early evaluation of intracerebral hemorrhage. J Neurosurg. 1990 Feb;72(2):195-9. doi: 10.3171/jns.1990.72.2.0195.
- Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M. Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke. 1998 Sep;29(9):1806-9. doi: 10.1161/01.str.29.9.1806.
- Koskinen LO, Olivecrona M, Grande PO. Severe traumatic brain injury management and clinical outcome using the Lund concept. Neuroscience. 2014 Dec 26;283:245-55. doi: 10.1016/j.neuroscience.2014.06.039. Epub 2014 Jun 25.
- Stocchetti N, Pagan F, Calappi E, Canavesi K, Beretta L, Citerio G, Cormio M, Colombo A. Inaccurate early assessment of neurological severity in head injury. J Neurotrauma. 2004 Sep;21(9):1131-40. doi: 10.1089/neu.2004.21.1131.
- Oddo M, Crippa IA, Mehta S, Menon D, Payen JF, Taccone FS, Citerio G. Optimizing sedation in patients with acute brain injury. Crit Care. 2016 May 5;20(1):128. doi: 10.1186/s13054-016-1294-5.
- Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996 Oct;27(10):1783-7. doi: 10.1161/01.str.27.10.1783.
- Stalhammar D, Starmark JE, Holmgren E, Eriksson N, Nordstrom CH, Fedders O, Rosander B. Assessment of responsiveness in acute cerebral disorders. A multicentre study on the reaction level scale (RLS 85). Acta Neurochir (Wien). 1988;90(3-4):73-80. doi: 10.1007/BF01560558.
- Pejtersen JH, Kristensen TS, Borg V, Bjorner JB. The second version of the Copenhagen Psychosocial Questionnaire. Scand J Public Health. 2010 Feb;38(3 Suppl):8-24. doi: 10.1177/1403494809349858.
- Wallace JD, Levy LL. Blood pressure after stroke. JAMA. 1981 Nov 13;246(19):2177-80.
- Harper G, Castleden CM, Potter JF. Factors affecting changes in blood pressure after acute stroke. Stroke. 1994 Sep;25(9):1726-9. doi: 10.1161/01.str.25.9.1726.
- Ong TZ, Raymond AA. Risk factors for stroke and predictors of one-month mortality. Singapore Med J. 2002 Oct;43(10):517-21.
- Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, Cohen WA. Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke. 1999 Oct;30(10):2025-32. doi: 10.1161/01.str.30.10.2025.
- Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology. 1994 Aug;44(8):1379-84. doi: 10.1212/wnl.44.8.1379.
- Zhou JF, Wang JY, Luo YE, Chen HH. Influence of hypertension, lipometabolism disorders, obesity and other lifestyles on spontaneous intracerebral hemorrhage. Biomed Environ Sci. 2003 Sep;16(3):295-303.
- Kazui S, Minematsu K, Yamamoto H, Sawada T, Yamaguchi T. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke. 1997 Dec;28(12):2370-5. doi: 10.1161/01.str.28.12.2370.
- Gebel JM Jr, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, Spilker J, Tomsick TA, Duldner J, Broderick JP. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke. 2002 Nov;33(11):2631-5. doi: 10.1161/01.str.0000035284.12699.84.
- Carhuapoma JR, Hanley DF, Banerjee M, Beauchamp NJ. Brain edema after human cerebral hemorrhage: a magnetic resonance imaging volumetric analysis. J Neurosurg Anesthesiol. 2003 Jul;15(3):230-3. doi: 10.1097/00008506-200307000-00010.
- Delcourt C, Huang Y, Wang J, Heeley E, Lindley R, Stapf C, Tzourio C, Arima H, Parsons M, Sun J, Neal B, Chalmers J, Anderson C; INTERACT2 Investigators. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). Int J Stroke. 2010 Apr;5(2):110-6. doi: 10.1111/j.1747-4949.2010.00415.x.
- Qureshi AI, Mohammad YM, Yahia AM, Suarez JI, Siddiqui AM, Kirmani JF, Suri MF, Kolb J, Zaidat OO. A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med. 2005 Jan-Feb;20(1):34-42. doi: 10.1177/0885066604271619.
- Terayama Y, Tanahashi N, Fukuuchi Y, Gotoh F. Prognostic value of admission blood pressure in patients with intracerebral hemorrhage. Keio Cooperative Stroke Study. Stroke. 1997 Jun;28(6):1185-8. doi: 10.1161/01.str.28.6.1185.
- Manning L, Hirakawa Y, Arima H, Wang X, Chalmers J, Wang J, Lindley R, Heeley E, Delcourt C, Neal B, Lavados P, Davis SM, Tzourio C, Huang Y, Stapf C, Woodward M, Rothwell PM, Robinson TG, Anderson CS; INTERACT2 investigators. Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurol. 2014 Apr;13(4):364-73. doi: 10.1016/S1474-4422(14)70018-3. Epub 2014 Feb 13.
- Kate MP, Hansen MB, Mouridsen K, Ostergaard L, Choi V, Gould BE, McCourt R, Hill MD, Demchuk AM, Coutts SB, Dowlatshahi D, Emery DJ, Buck BH, Butcher KS; ICHADAPT Investigators. Blood pressure reduction does not reduce perihematoma oxygenation: a CT perfusion study. J Cereb Blood Flow Metab. 2014 Jan;34(1):81-6. doi: 10.1038/jcbfm.2013.164. Epub 2013 Sep 18.
- Boulouis G, Morotti A, Goldstein JN, Charidimou A. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):339-345. doi: 10.1136/jnnp-2016-315346. Epub 2017 Feb 18.
- Egawa S, Hifumi T, Kawakita K, Okauchi M, Shindo A, Kawanishi M, Tamiya T, Kuroda Y. Impact of neurointensivist-managed intensive care unit implementation on patient outcomes after aneurysmal subarachnoid hemorrhage. J Crit Care. 2016 Apr;32:52-5. doi: 10.1016/j.jcrc.2015.11.008. Epub 2015 Dec 2.
- Tanaka E, Koga M, Kobayashi J, Kario K, Kamiyama K, Furui E, Shiokawa Y, Hasegawa Y, Okuda S, Todo K, Kimura K, Okada Y, Okata T, Arihiro S, Sato S, Yamagami H, Nagatsuka K, Minematsu K, Toyoda K. Blood pressure variability on antihypertensive therapy in acute intracerebral hemorrhage: the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-intracerebral hemorrhage study. Stroke. 2014 Aug;45(8):2275-9. doi: 10.1161/STROKEAHA.114.005420. Epub 2014 Jun 26.
- Li M, Zhang Y, Wu KS, Hu YH. Assessment of the effect of continuous sedation with mechanical ventilation on adrenal insufficiency in patients with traumatic brain injury. J Investig Med. 2016 Mar;64(3):752-8. doi: 10.1136/jim-2015-000012. Epub 2016 Feb 10.
- Balestreri M, Czosnyka M, Chatfield DA, Steiner LA, Schmidt EA, Smielewski P, Matta B, Pickard JD. Predictive value of Glasgow Coma Scale after brain trauma: change in trend over the past ten years. J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):161-2.
- Engelhard K, Reeker W, Kochs E, Werner C. Effect of remifentanil on intracranial pressure and cerebral blood flow velocity in patients with head trauma. Acta Anaesthesiol Scand. 2004 Apr;48(4):396-9. doi: 10.1111/j.0001-5172.2004.00348.x.
- Yokota H, Yokoyama K, Noguchi H, Nishioka T, Umegaki O, Komatsu H, Sakaki T. Post-operative dexmedetomidine-based sedation after uneventful intracranial surgery for unruptured cerebral aneurysm: comparison with propofol-based sedation. Neurocrit Care. 2011 Apr;14(2):182-7. doi: 10.1007/s12028-010-9485-4.
- Grof TM, Bledsoe KA. Evaluating the use of dexmedetomidine in neurocritical care patients. Neurocrit Care. 2010 Jun;12(3):356-61. doi: 10.1007/s12028-008-9156-x.
- Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996 Aug;27(8):1304-5. doi: 10.1161/01.str.27.8.1304.
- Topolovec-Vranic J, Canzian S, Innis J, Pollmann-Mudryj MA, McFarlan AW, Baker AJ. Patient satisfaction and documentation of pain assessments and management after implementing the adult nonverbal pain scale. Am J Crit Care. 2010 Jul;19(4):345-54; quiz 355. doi: 10.4037/ajcc2010247.
- Dong R, Li F, Xu Y, Chen P, Maegele M, Yang H, Chen W. Safety and efficacy of applying sufficient analgesia combined with a minimal sedation program as an early antihypertensive treatment for spontaneous intracerebral hemorrhage: a randomized controlled trial. Trials. 2018 Nov 6;19(1):607. doi: 10.1186/s13063-018-2943-6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 6, 2017
Primary Completion (Actual)
February 14, 2021
Study Completion (Actual)
May 15, 2021
Study Registration Dates
First Submitted
June 26, 2017
First Submitted That Met QC Criteria
June 29, 2017
First Posted (Actual)
July 2, 2017
Study Record Updates
Last Update Posted (Estimated)
December 7, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201704004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Pressure Variability
-
Cedars-Sinai Medical CenterNot yet recruitingBlood Pressure Variability
-
University of PittsburghZOLL FoundationCompletedBlood Pressure | Heart Rate VariabilityUnited States
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Rate Variability | Blood Pressure Variability | Pressor Response | Baroreflex Sensitivity | Arterial CatecholaminesUnited States
-
St Carlos Hospital, Madrid, SpainRecruitingHypertension | Blood Pressure Disorders | Renal Denervation | Blood Pressure Variability | Increased Variability | Sympathetic DysautonomiaSpain
-
CareTaker Medical LLCUniversity of Virginia; Yale School of Medicine; Orange County Research CenterCompletedBlood Pressure | Heart Rate Variability | Cardiac Output | Left Ventricular Ejection TimeUnited States
-
University of EdinburghPeking Union Medical CollegeCompletedBlood Pressure | Heart Rate VariabilityChina
-
University of MalayaCompletedCardiovascular Diseases | Hypertension | Blood Pressure VariabilityMalaysia
-
Istituto Auxologico ItalianoBayerCompletedHypertension | High Blood Pressure VariabilityChina, Greece, Italy
-
University Health Network, TorontoCompletedVital Signs Monitoring | Blood Pressure, Heart Rate, Respiratory Rate, Heart Rate Variability, Stress Index, Vital Signs MonitoringCanada
-
Miao-Yi ChenCompletedAnxiety | Blood Pressure | Heart Rate Variability | Eye Movement Desensitization and Reprocessing InterventionTaiwan
Clinical Trials on Analgesia-first minimal sedation
-
Poitiers University HospitalCompletedFracture | Dislocation | Reality Device | Reduction ProcedureFrance
-
MemorialCare Health SystemRecruitingRespiratory Failure | Mechanical VentilationUnited States
-
University Health Network, TorontoWithdrawnAwake Craniotomy for Brain Tumour SurgeryCanada
-
Pontificia Universidad Catolica de ChileUnknownCritical Illness | Respiratory Insufficiency | Ventilation, MechanicalChile
-
Region SkaneThe George Institute for Global Health, Australia; Copenhagen Trial Unit, Center... and other collaboratorsRecruitingHypoxia, Brain | Cardiac Arrest With Successful ResuscitationSweden, Finland, Australia, Switzerland, New Zealand, Luxembourg, Germany
-
Region SkaneLund University; Helsinki University Central Hospital; The George Institute for... and other collaboratorsRecruitingCognitive Impairment | Caregiver Burden | Hypoxia, Brain | Cardiac Arrest With Successful ResuscitationSweden, Finland, New Zealand, Australia, Germany, Luxembourg
-
Boston Children's HospitalCompletedSedation | Mechanical VentilationUnited States
-
McGill University Health Centre/Research Institute...CompletedAnesthesia, Local | Hand Injuries | Quality of Recovery | Hand Surgery | Hand Fracture | Hand Tendon InjuryCanada
-
Tanta UniversityNot yet recruitingBariatric Surgery Candidate
-
Inonu UniversityCompletedAnalgesia | Anesthesia | In-vitro FertilizationTurkey